0000950170-23-051733.txt : 20231003 0000950170-23-051733.hdr.sgml : 20231003 20231003192118 ACCESSION NUMBER: 0000950170-23-051733 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230929 FILED AS OF DATE: 20231003 DATE AS OF CHANGE: 20231003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aziz Kabeer CENTRAL INDEX KEY: 0001914847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41331 FILM NUMBER: 231306111 MAIL ADDRESS: STREET 1: 376 MANHATTAN AVENUE APT. 3 CITY: BROOKLYN STATE: NY ZIP: 11211 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AN2 Therapeutics, Inc. CENTRAL INDEX KEY: 0001880438 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820606654 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 BUSINESS PHONE: (650) 331-9090 MAIL ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 4 1 ownership.xml 4 X0508 4 2023-09-29 0001880438 AN2 Therapeutics, Inc. ANTX 0001914847 Aziz Kabeer C/O AN2 THERAPEUTICS, INC. 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 true false true false false Common Stock 2023-09-29 4 S false 83337 16.28 D 2086343 I By Adjuvant Global Health Technology Fund, L.P. Common Stock 2023-09-29 4 S false 15764 16.28 D 394639 I By Adjuvant Global Health Technology Fund DE, L.P. Common Stock 2023-10-02 4 S false 4770 16.07 D 2081573 I By Adjuvant Global Health Technology Fund, L.P. Common Stock 2023-10-02 4 S false 902 16.07 D 393737 I By Adjuvant Global Health Technology Fund DE, L.P. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Kabeer Aziz 2023-10-03